DSY Dassault Systemes SA

Dassault Systèmes: disclosure of trading in own shares

Dassault Systèmes: disclosure of trading in own shares

Vélizy-Villacoublay, November 2, 2020

DISCLOSURE OF TRADING IN OWN SHARES

(Repurchase program decided by the General Meeting of Shareholders of May 26, 2020)

Issuer: Dassault Systèmes SE

Type of securities: ordinary shares

Period: October 23, 2020 to October 28, 2020

Detailed information (presentation by day and by market and transaction-by-transaction details) can be consulted on the website of Dassault Systèmes:

Presentation of the trading in own shares by day and by market

Name of issuerIdentification code of the issuerDate of tradingIdentification code of the financial instrumentDaily total volume (in number of shares)Daily weighted average acquisition price of the shares*Market
DASSAULT SYSTEMES96950065LBWY0APQIM8623-Oct-2020FR000013065050,500148.1535XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM8623-Oct-2020FR000013065014,700148.2776CHIX
DASSAULT SYSTEMES96950065LBWY0APQIM8623-Oct-2020FR00001306504,800148.3031TRQX
DASSAULT SYSTEMES96950065LBWY0APQIM8623-Oct-2020FR000013065020,500148.2651BATE
DASSAULT SYSTEMES96950065LBWY0APQIM8626-Oct-2020FR000013065062,698146.8464XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM8626-Oct-2020FR000013065015,631146.7930CHIX
DASSAULT SYSTEMES96950065LBWY0APQIM8626-Oct-2020FR00001306505,090146.7446TRQX
DASSAULT SYSTEMES96950065LBWY0APQIM8626-Oct-2020FR000013065020,881146.9115BATE
DASSAULT SYSTEMES96950065LBWY0APQIM8627-Oct-2020FR000013065034,809145.6061XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM8627-Oct-2020FR00001306509,575145.7094CHIX
DASSAULT SYSTEMES96950065LBWY0APQIM8627-Oct-2020FR00001306505,153145.8114TRQX
DASSAULT SYSTEMES96950065LBWY0APQIM8627-Oct-2020FR000013065011,025145.7204BATE
DASSAULT SYSTEMES96950065LBWY0APQIM8628-Oct-2020FR000013065056,976145.7001XPAR
DASSAULT SYSTEMES96950065LBWY0APQIM8628-Oct-2020FR000013065012,519145.7481CHIX
DASSAULT SYSTEMES96950065LBWY0APQIM8628-Oct-2020FR00001306504,335145.4626TRQX
DASSAULT SYSTEMES96950065LBWY0APQIM8628-Oct-2020FR000013065010,777145.6556BATE

(*)The weighted average unit price is a rounded price

CONTACTS:

Dassault Systèmes:

Investor Relations

François-José Bordonado/Béatrix Martinez

24

 ; 

Attachment

EN
02/11/2020

Underlying

DSYDassault Systemes SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

Free Trial
DSY Dassault System...

Dassault Systemes Sa: 2 directors

Two Directors at Dassault Systemes Sa bought 30,495 shares at between 24.530EUR and 24.661EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

DSY DASSAULT SYSTEMES SA
11/04/25 November 4, 2025 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi ...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration w...

October 28, 2025 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Mise à jour : Dassault Systèmes : Medidata étend sa collaboration avec...

Mise à jour : Dassault Systèmes : Medidata étend sa collaboration avec Sanofi pour développer de nouvelles thérapies visant à améliorer le parcours patient Medidata étend sa collaboration avec Sanofi pour développer de nouvelles thérapies visant à améliorer le parcours patient Une collaboration de plus de dix ans renforcée autour des Medidata Experiences, a pour l’objectif d’optimiser les processus et les données cliniques en améliorant la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des solutions numériques pour les essais cliniques...

October 28, 2025 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Mise à jour : Dassault Systèmes : Sanofi renforce sa collaboration ave...

Mise à jour : Dassault Systèmes : Sanofi renforce sa collaboration avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Sanofi renforce sa collaboration avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Une collaboration de plus de dix ans élargie autour des Medidata Experiences, permettant à Sanofi d’optimiser ses opérations, d’affiner la qualité de ses données et d’améliorer la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des soluti...

October 28, 2025 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi ...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration w...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch